Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by WORKINMONTANAon Feb 28, 2019 6:54pm

159 Views

Post# 29425949

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Next few weeks....

This is an extremely good break down of the failure rate compared to the further SP potential. I don’t quite understand why senior investors (market makers) are not biting yet. I heard some street blokes say $KALY is a shot in the dark still. IMO it’s like finding one of the Wonka Bar Golden tickets.

Jack4000 wrote:
Middle of pahse 2 between a and b the fail rate is 30%.

Once you hit phase three, the cost of testing and administrating skyrockets but the chance of failure goes down to 10%.

Price of stock now, is 7 cents with the company faing a 30% fail rate thus, you are looking at a $2.50 stock in two years with a 70% chance of achieving it.

So, your payoff - IF you had ten stocks with identical odds and prices would average out to be 70% of $2.50 which is $1.75

And, glad you liked the $2.50. it goes up $2 per year until 2029 accoding to the market report they put out a couple years ago. Which is why to me, dillution doesn't mean squat as I optimitiscly (but well within the market report's parameters) peg the SP in 2029 at $14 or up.